Tai-Shin Pharmaceutical Q4 2025 Financial Report
Key facts
- Tai-Shin Pharmaceutical Q4 2025 Financial Report
- Tai-Shin Pharmaceutical Co., Ltd. reported a basic EPS of -0.55 NTD and an operating revenue of 0.09 billion NTD for Q4 2025, with a net loss after tax of 0.84 billion NTD.
- Source: PR Times
- Date: December 1, 2025
Direct answer
Tai-Shin Pharmaceutical Co., Ltd. reported a basic EPS of -0.55 NTD and an operating revenue of 0.09 billion NTD for Q4 2025, with a net loss after tax of 0.84 billion NTD.
- Citation
- Tai-Shin Pharmaceutical Q4 2025 Financial Report (December 1, 2025), PR Times
- Source
- PR Times
- Date
- December 1, 2025
Tai-Shin Pharmaceutical Co., Ltd. reported a basic EPS of -0.55 NTD and an operating revenue of 0.09 billion NTD for Q4 2025, with a net loss after tax of 0.84 billion NTD.
📋 Article Processing Timeline
- 📰 Published: December 1, 2025 at 09:00
- 🔍 Collected: April 7, 2026 at 08:00 (3047h 0m after Published)
- 🤖 AI Analyzed: April 8, 2026 at 00:21 (16h 21m after Collected)
Company Code: 6838, Company Name: Tai-Shin Pharmaceutical Co., Ltd., Industry: Biotechnology and Medical Care Industry, Year/Quarter: 2025 Q4, Basic Earnings Per Share: -0.55 NTD, Operating Revenue: 0.09 billion NTD, Net Income After Tax: -0.84 billion NTD.
FAQ
What are the key facts in this article?
Tai-Shin Pharmaceutical Co., Ltd. reported a basic EPS of -0.55 NTD and an operating revenue of 0.09 billion NTD for Q4 2025, with a net loss after tax of 0.84 billion NTD.
What is the direct answer?
Tai-Shin Pharmaceutical Co., Ltd. reported a basic EPS of -0.55 NTD and an operating revenue of 0.09 billion NTD for Q4 2025, with a net loss after tax of 0.84 billion NTD.
What is the source and date?
PR Times: https://openapi.twse.com.tw/financial/twse-fin-6838-2025Q4 | December 1, 2025